Physician profile
Farshad Nowzari
NPI 1689741423
$6,796.40
in general payments reported to CMS, 2019-2025
24 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.41 · 2020: $375 · 2021: $450 · 2022: $2,928 · 2023: $2,034 · 2024: $636 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714 · Travel and Lodging: $794 · Consulting Fee: $380 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.68 |
| Travel and Lodging | $794.37 |
| Consulting Fee | $380.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,527.57 | 2020-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $1,119.99 | 2023 | Aquabeam Robotic System |
| C. R. Bard, INC. & Subsidiaries | $900.00 | 2022-2023 | |
| Becton, Dickinson and Company | $300.00 | 2022 | |
| Myriad Genetic Laboratories, INC. | $287.97 | 2022-2025 | Prolaris |
| Endo Pharmaceuticals INC. | $266.56 | 2020-2024 | Xiaflex, Aveed |
| Medtronic, INC. | $248.35 | 2021-2023 | Surgipro Ll, Lapro-Clip |
| Sumitomo Pharma America, INC. | $237.28 | 2023-2025 | Gemtesa, Orgovyx |
| Neotract INC. | $229.91 | 2020 | |
| Janssen Biotech, INC. | $171.62 | 2023-2025 | Erleada |
| Myovant Sciences INC. | $76.43 | 2021 | |
| Laborie Medical Technologies Corp. | $59.89 | 2024-2025 | Urgent PC Neuromodulation System, Optilume Bph Drug Coated Balloon Catheter |
| Dendreon Pharmaceuticals LLC | $57.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.89 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $42.41 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $36.94 | 2025 | |
| Abbvie INC. | $28.12 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $27.28 | 2023 | Lynparza |
| Gilead Sciences, INC. | $25.26 | 2025 | |
| Endo USA, INC. | $24.70 | 2024 | Xiaflex |
| Coloplast Corp | $21.04 | 2022 | |
| Axonics, INC. | $20.00 | 2020 | |
| Boston Scientific Corporation | $15.41 | 2019 | |
| Mission Pharmacal Company | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farshad Nowzari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.